Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., the post-merger successor to Leisure Acquisition Corp. (Nasdaq: LACQ), filed an 8-K with the SEC on June 27, 2022. Leisure Acquisition Corp. was sponsored by Hydra Management LLC and completed its IPO in 2018, initially targeting the entertainment and leisure sector. The SPAC subsequently redirected its focus to the healthcare and life sciences space, completing a business combination with Ensysce Biosciences in June 2021. Ensysce is a clinical-stage pharmaceutical company developing abuse-deterrent opioid therapies and rapid drug detection technologies. The combined company operates in the specialty pharmaceuticals segment under Nasdaq ticker ENSC. Sign up on SpacDesk for full filings, transaction history, and analytics on LACQ and the broader SPAC market.